论文部分内容阅读
目的:总结曲妥珠单抗联合阿霉素与曲妥珠单抗联合阿霉素脂质体治疗人表皮生长因子-2(HER-2)过度表达的乳腺癌的疗效和安全性。方法:经细胞学证实的HER-2过度表达的60例乳腺癌患者,25例接受曲妥珠单抗联合阿霉素化疗方案(A组),35例接受曲妥珠单抗联合阿霉素脂质体(B组)方案化疗。参照实体瘤疗效评价标准进行疗效判定,按照美国国立研究院通用毒性标准评价不良反应。结果:58例患者可评价疗效,A组完全缓解率为16.0%,部分缓解率为20.0%,总有效率为36.0%;B组完全缓解率为18.2%,部分缓解率为30.3%,总有效率为48.5%;B组患者的生存时间比A组患者的生存时间长;A组和B组的主要不良反应为粒细胞减少、心脏毒性、恶心呕吐等。结论:曲妥珠单抗联合阿霉素脂质体可以提高治疗HER-2阳性表达的乳腺癌患者的有效率,并且延长患者的生存时间。
OBJECTIVE: To summarize the efficacy and safety of trastuzumab combined with doxorubicin and trastuzumab in combination with doxorubicin liposome for the treatment of breast cancer overexpressing human epidermal growth factor-2 (HER-2). METHODS: Sixty human breast cancer patients with overexpression of HER-2 were identified by cytology. 25 patients received trastuzumab plus doxorubicin chemotherapy (group A) and 35 received trastuzumab plus doxorubicin Liposomes (Group B) regimen chemotherapy. Reference to the evaluation criteria for the efficacy of solid tumors to determine the efficacy, according to the National Institute of General toxicity standard assessment of adverse reactions. Results: In 58 patients, the complete remission rate was 16.0%, the partial remission rate was 20.0% and the total effective rate was 36.0%. The complete remission rate was 18.2% in group B, and the partial remission rate was 30.3% The efficiency was 48.5%. The survival time of patients in group B was longer than that of patients in group A. The main adverse reactions of group A and B were neutropenia, cardiotoxicity, nausea and vomiting. Conclusion: Trastuzumab combined with doxorubicin liposomes can improve the efficiency of the treatment of HER-2-positive breast cancer patients, and prolong the survival time of patients.